Cartherics awarded grant to accelerate clinical manufacturing of cancer therapy
Make us a preferred source
Make us a preferred source on Google
The news: Australian biotechnology company Cartherics has been awarded a $456,000 (USD300,000) G-Rex grant to support clinical manufacturing of its lead ovarian cancer treatment product CTH-401 for upcoming clinical trials.
The numbers: The grant is part of a $30.4 million (USD20 million) initiative by ScaleReady, Wilson Wolf Manufacturing, and CellReady.
The context: The funding will be used to purchase equipment and reagents to support Cartherics' research, development and manufacturing programs. CTH-401 has demonstrated complete eradication of human ovarian cancer cells in mice trials.
The G-Rex grant will support the company's integrated approach to product development and manufacturing within a single facility.
Melbourne-based Cartherics is developing cell-based immunotherapies for cancer treatment, with a portfolio of CAR-T and CAR-NK cell products.
What they said: "We've taken an ambitious step to streamline our product R&D and manufacturing under one roof. This integrated approach positions us to seamlessly transition from pioneering pre-clinical research to clinical manufacturing — all within the same facility," Cartherics chief executive professor Alan Trounson said.
Wilson Wolf and CellReady CEO John Wilson said: "G-Rex is the ideal platform for the large-scale manufacture of Cartherics' allogenic [off-the-shelf] CAR-iNK cells. With the allo CAR-iNK's having demonstrated complete eradication of human ovarian cancer cells in mice, we are eager to help Cartherics optimise manufacturing for application in human trials".
The source: Cartherics press release
